San Diego-based Viking Therapeutics marked itself as a serious competitor within the weight loss drug marketplace in February after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when offered like a weekly injection As well as in March the company